These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33280052)

  • 1. Influence of a low-dose tacrolimus protocol on the appearance of de novo donor-specific antibodies during 7 years of follow-up after renal transplantation.
    Unagami K; Ishida H; Furusawa M; Kitajima K; Hirai T; Kakuta Y; Toki D; Shimizu T; Omoto K; Okumi M; Nitta K; Tanabe K
    Nephrol Dial Transplant; 2021 May; 36(6):1120-1129. PubMed ID: 33280052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
    Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE
    Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA B eplet mismatches in the context of delayed graft function and low tacrolimus trough levels are risk factors influencing the generation of de novo donor-specific antibodies and acute rejection in the early stage after kidney transplantation.
    Gao S; Gong H; Li M; Lan P; Zhang M; Kuang P; Zhang Y; Hu X; Ding C; Li Y; Ding X; Xue W; Zheng J
    Transpl Immunol; 2023 Dec; 81():101955. PubMed ID: 37931666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.
    Jung HY; Cho SY; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2019 Apr; 34(12):e103. PubMed ID: 30940998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
    Wiebe C; Rush DN; Nevins TE; Birk PE; Blydt-Hansen T; Gibson IW; Goldberg A; Ho J; Karpinski M; Pochinco D; Sharma A; Storsley L; Matas AJ; Nickerson PW
    J Am Soc Nephrol; 2017 Nov; 28(11):3353-3362. PubMed ID: 28729289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.
    Davis S; Gralla J; Klem P; Stites E; Wiseman A; Cooper JE
    Transplantation; 2020 Apr; 104(4):881-887. PubMed ID: 32224815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients.
    Jung HY; Seo MY; Jeon Y; Huh KH; Park JB; Jung CW; Lee S; Han SY; Ro H; Yang J; Ahn C; Choi JY; Cho JH; Park SH; Kim YL; Kim CD
    PLoS One; 2020; 15(7):e0235418. PubMed ID: 32614859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High tacrolimus intra-patient variability is associated with graft rejection, and
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Hebral AL; Bellière J; Kamar N
    World J Gastroenterol; 2018 Apr; 24(16):1795-1802. PubMed ID: 29713132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk.
    Baghai Arassi M; Gauche L; Schmidt J; Höcker B; Rieger S; Süsal C; Tönshoff B; Fichtner A
    Pediatr Nephrol; 2022 Oct; 37(10):2503-2514. PubMed ID: 35166920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
    Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
    PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo Prograf versus de novo Advagraf: are trough level profile curves similar?
    Sarvary E; Wagner L; Telkes G; Gaman G; Varga M; Gaal I; Mathe Z; Chmel R; Fehervari I; Langer RM
    Transplant Proc; 2014; 46(6):2164-7. PubMed ID: 25131131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtle Changes in Tacrolimus Levels Have an Impact on Early Donor-Specific Antibodies in Kidney Transplantation.
    Henderson M; Awdishu L; Morris GP; Fabbri K; Shah M; Khan A; Kerr J
    Prog Transplant; 2023 Dec; 33(4):335-340. PubMed ID: 37941352
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients.
    Lee H; Min JW; Kang H; Lee H; Eum SH; Park Y; Yang CW; Chung BH; Oh EJ
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
    Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
    Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
    Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
    Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation.
    Žilinská Z; Dedinská I; Breza J; Laca L
    Transplant Proc; 2016 Oct; 48(8):2637-2643. PubMed ID: 27788794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.